DrugPatentWatch Database Preview

CHANTIX Drug Profile

  Purchase this report

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Chantix, and what generic alternatives are available?

Chantix is a drug marketed by Pf Prism Cv and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty-two patent family members in fifty-six countries.

The generic ingredient in CHANTIX is varenicline tartrate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.

Summary for CHANTIX

International Patents:	182
US Patents:	3
Applicants:	1
NDAs:	1
Suppliers / Packagers:	8
Clinical Trials:	61
Formulation / Manufacturing:	see details
DailyMed Link:	CHANTIX at DailyMed

Pharmacology for CHANTIX

Drug Class	Partial Cholinergic Nicotinic Agonist
Mechanism of Action	Partial Cholinergic Nicotinic Agonists

Medical Subject Heading (MeSH) Categories for CHANTIX

Nicotinic Agonists

US Patents and Regulatory Information for CHANTIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	CHANTIX	varenicline tartrate	TABLET;ORAL	021928-001	May 10, 2006		RX	Yes	No			Y	Y
Pf Prism Cv	CHANTIX	varenicline tartrate	TABLET;ORAL	021928-002	May 10, 2006		RX	Yes	Yes			Y	Y
Pf Prism Cv	CHANTIX	varenicline tartrate	TABLET;ORAL	021928-001	May 10, 2006		RX	Yes	No
Pf Prism Cv	CHANTIX	varenicline tartrate	TABLET;ORAL	021928-002	May 10, 2006		RX	Yes	Yes			Y	Y

  Purchase this report

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for CHANTIX

Drugname	Dosage	Strength	RLD	Submissiondate
	Tablets	0.5 mg and 1 mg		2010-05-10

Non-Orange Book US Patents for CHANTIX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,951,938	Aryl fused azapolycyclic compounds
7,205,300	Aryl fused azapolycyclic compounds
6,605,610	Aryl fused azapolycyclic compounds
7,144,882	Aryl fused azapolycyclic compounds

  Purchase this report

see a sample report or, see our see our flat-rate plans

International Patents for CHANTIX

Country	Document Number	Estimated Expiration
Canada	2316921
Dominican Republic	P2002000392
Panama	8545101
Japan	3779682

Supplementary Protection Certificates for CHANTIX

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
5	Finland
C0039	France		PRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926
2008 00031	Denmark
2008010	Lithuania		PRODUCT NAME: VARENICLINUM TARTRAT; REG. NO/DATE: EU/1/06/360/001-010 20060926